See the newly-re-launched Impactiviti Collection e-newsletter! Here’s a link to the on-line version; you can sign up to receive the Connection (~every two weeks) right here.
FDA clears new Novartis combo drug for HBP – The FDA has approved Novartis’ Valturna (aliskiren and valsartan) tablets, a medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS)…more
…but says “No” to Sanofi‘s insomnia drug. However, Sanofi did complete the purchase of the Merck half of Merial.
Amgen‘s “mobile rep” strategy for product launch – Amgen Inc. is hiring flexible, mobile sales representatives as it builds a primary care sales force, a strategy that may allow for a more efficient product launch ahead of the expected regulatory approval of osteoporosis treatment denosumab in mid-October. The launch is likely to be the most important yet for the Thousand Oaks, Calif., biotech, as the drug focuses on primary care physicians in the U.S., a much wider target than its traditional specialty focus. Amgen’s job is made more difficult because the company, unlike traditional pharmaceuticals, is creating the sales force from scratch…more
Virtual Hospital Training. Have to train Hospital sales reps? Maybe an interactive virtual hospital will help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!
Big picture – what about the future of Big Pharma (I’ve believed for years that a de-verticalization of pharma companies into more compact and focused entities would be very smart). Take a look at this analysis.
JUST FOR FUN
Yummmmmy! And, a Friday bonus: Transparency – not!
Subscribe to the Impactiviti blog via e-mail
Connect with Steve Woodruff
Leave a Reply